{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:36:57Z","timestamp":1772120217211,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>OSU6162, a monoamine stabilizer, has demonstrated efficacy in reducing alcohol and anxiety-related behaviors in preclinical settings. In a previous randomized, double-blind, placebo-controlled trial involving patients with alcohol dependence (AD), OSU6162 significantly reduced craving for alcohol but did not alter drinking behaviors. This retrospective secondary analysis explores whether genetic predispositions related to AD and associated traits might influence the response to OSU6162 treatment in original trial participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Polygenic risk scores (PRSs) were calculated for 48 AD patients using PRSice-2 and genome-wide association study (GWAS) data for (i) alcohol use disorder and alcohol consumption, (ii) problematic alcohol use, (iii) drinks per week, (iv) major depression, and (v) anxiety (case-control comparisons and quantitative anxiety factor scores). Linear regression analyses, adjusted for population stratification, assessed interaction effects between PRSs and treatment type (OSU6162 or placebo) on various clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Significant interactions were found between treatment type and anxiety factor score PRS at the genome-wide significance threshold. In the OSU6162-treated group, a higher anxiety PRS was associated with reductions in the number of drinks consumed (FDR\u2009=\u20090.0017), percentage of heavy drinking days (FDR\u2009=\u20090.0060), and percentage of drinking days (FDR\u2009=\u20090.0017), with a trend toward reduced blood phosphatidylethanol (PEth) levels (FDR\u2009=\u20090.068). These associations were absent in the placebo group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These preliminary findings suggest that anxiety PRS may help predict response to OSU6162 treatment in AD. Further research with larger cohorts and more comprehensive genetic data is needed to confirm these results and advance personalized medicine approaches for alcohol use disorder.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s43440-025-00707-8","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T20:32:21Z","timestamp":1741725141000},"page":"840-849","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genetic liability for anxiety and treatment response to the monoamine stabilizer OSU6162 in alcohol dependence: a retrospective secondary analysis"],"prefix":"10.1007","volume":"77","author":[{"given":"Mun-Gwan","family":"Hong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lotfi","family":"Khemiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joar","family":"Guterstam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Franck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitya","family":"Jayaram-Lindstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe A.","family":"Melas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"707_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/978-3-642-28720-6_170","volume":"13","author":"B Soderpalm","year":"2013","unstructured":"Soderpalm B, Ericson M. Neurocircuitry involved in the development of alcohol addiction: the dopamine system and its access points. Curr Top Behav Neurosci. 2013;13:127\u201361.","journal-title":"Curr Top Behav Neurosci"},{"key":"707_CR2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/B978-0-12-385506-0.00010-7","volume":"98","author":"Y Sari","year":"2011","unstructured":"Sari Y, Johnson VR, Weedman JM. Role of the serotonergic system in alcohol dependence: from animal models to clinics. Prog Mol Biol Transl Sci. 2011;98:401\u201343.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"707_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0376-8716(02)00220-X","volume":"68","author":"L Burns","year":"2002","unstructured":"Burns L, Teesson M. Alcohol use disorders comorbid with anxiety, depression and drug use disorders. Findings from the Australian National survey of mental health and well being. Drug Alcohol Depend. 2002;68:299\u2013307.","journal-title":"Drug Alcohol Depend"},{"key":"707_CR4","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1017\/S0033291719001788","volume":"50","author":"S Virtanen","year":"2020","unstructured":"Virtanen S, Kuja-Halkola R, Mataix-Cols D, Jayaram-Lindstrom N, D\u2019Onofrio BM, Larsson H, et al. Comorbidity of substance misuse with anxiety-related and depressive disorders: a genetically informative population study of 3 million individuals in Sweden. Psychol Med. 2020;50:1706\u201315.","journal-title":"Psychol Med"},{"key":"707_CR5","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/ijnp\/pyx056","volume":"20","author":"P Belujon","year":"2017","unstructured":"Belujon P, Grace AA. Dopamine system dysregulation in major depressive disorders. Int J Neuropsychopharmacol. 2017;20:1036\u201346.","journal-title":"Int J Neuropsychopharmacol"},{"key":"707_CR6","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.biopsych.2020.06.018","volume":"88","author":"SR DeGroot","year":"2020","unstructured":"DeGroot SR, Zhao-Shea R, Chung L, Klenowski PM, Sun F, Molas S, et al. Midbrain dopamine controls Anxiety-like behavior by engaging unique interpeduncular nucleus microcircuitry. Biol Psychiatry. 2020;88:855\u201366.","journal-title":"Biol Psychiatry"},{"key":"707_CR7","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/B978-0-444-64125-0.00029-3","volume":"31","author":"AJ Lawther","year":"2020","unstructured":"Lawther AJ, Hale MW, Lowry CA. Chapter 29 - Serotonin and the neurobiology of anxious States. Handb Behav Neurosci. 2020;31:505\u201320.","journal-title":"Handb Behav Neurosci"},{"key":"707_CR8","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapsychiatry.2015.0584","volume":"72","author":"BF Grant","year":"2015","unstructured":"Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, et al. Epidemiology of DSM-5 alcohol use disorder: results from the National epidemiologic survey on alcohol and related conditions III. JAMA Psychiatry. 2015;72:757\u201366.","journal-title":"JAMA Psychiatry"},{"key":"707_CR9","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1001\/jamapsychiatry.2017.2161","volume":"74","author":"BF Grant","year":"2017","unstructured":"Grant BF, Chou SP, Saha TD, Pickering RP, Kerridge BT, Ruan WJ, et al. Prevalence of 12-Month alcohol use, High-Risk drinking, and DSM-IV alcohol use disorder in the united States, 2001\u20132002 to 2012\u20132013: results from the National epidemiologic survey on alcohol and related conditions. JAMA Psychiatry. 2017;74:911\u201323.","journal-title":"JAMA Psychiatry"},{"key":"707_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.drugalcdep.2008.07.018","volume":"99","author":"TL Mark","year":"2009","unstructured":"Mark TL, Kassed CA, Vandivort-Warren R, Levit KR, Kranzler HR. Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend. 2009;99:345\u20139.","journal-title":"Drug Alcohol Depend"},{"key":"707_CR11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jpsychires.2015.07.016","volume":"69","author":"AD Rubinsky","year":"2015","unstructured":"Rubinsky AD, Chen C, Batki SL, Williams EC, Harris AH. Comparative utilization of pharmacotherapy for alcohol use disorder and other psychiatric disorders among U.S. Veterans health administration patients with dual diagnoses. J Psychiatr Res. 2015;69:150\u20137.","journal-title":"J Psychiatr Res"},{"key":"707_CR12","doi-asserted-by":"crossref","unstructured":"Srisurapanont M, Jarusuraisin N. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2005:CD001867.","DOI":"10.1002\/14651858.CD001867.pub2"},{"key":"707_CR13","doi-asserted-by":"crossref","unstructured":"Rosner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010:CD001867.","DOI":"10.1002\/14651858.CD001867.pub3"},{"key":"707_CR14","doi-asserted-by":"crossref","unstructured":"Rosner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010:CD004332.","DOI":"10.1002\/14651858.CD004332.pub2"},{"key":"707_CR15","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1038\/s41386-021-01097-0","volume":"46","author":"JM Biernacka","year":"2021","unstructured":"Biernacka JM, Coombes BJ, Batzler A, Ho AM, Geske JR, Frank J, et al. Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study. Neuropsychopharmacology. 2021;46:2132\u20139.","journal-title":"Neuropsychopharmacology"},{"key":"707_CR16","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.biopsych.2012.06.018","volume":"72","author":"P Steensland","year":"2012","unstructured":"Steensland P, Fredriksson I, Holst S, Feltmann K, Franck J, Schilstrom B, et al. The monoamine stabilizer (-)-OSU6162 attenuates voluntary ethanol intake and ethanol-induced dopamine output in nucleus accumbens. Biol Psychiatry. 2012;72:823\u201331.","journal-title":"Biol Psychiatry"},{"key":"707_CR17","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/adb.12613","volume":"24","author":"I Fredriksson","year":"2019","unstructured":"Fredriksson I, Wirf M, Steensland P. The monoamine stabilizer (-)-OSU6162 prevents the alcohol deprivation effect and improves motor impulsive behavior in rats. Addict Biol. 2019;24:471\u201384.","journal-title":"Addict Biol"},{"key":"707_CR18","doi-asserted-by":"publisher","first-page":"11856","DOI":"10.1038\/s41598-021-91215-1","volume":"11","author":"PA Melas","year":"2021","unstructured":"Melas PA, Wirf M, Andre H, Jayaram-Lindstrom N, Mathe AA, Steensland P. The monoamine stabilizer OSU6162 has anxiolytic-like properties and reduces voluntary alcohol intake in a genetic rat model of depression. Sci Rep. 2021;11:11856.","journal-title":"Sci Rep"},{"key":"707_CR19","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/adb.12304","volume":"21","author":"K Feltmann","year":"2016","unstructured":"Feltmann K, Fredriksson I, Wirf M, Schilstrom B, Steensland P. The monoamine stabilizer (-)-OSU6162 counteracts downregulated dopamine output in the nucleus accumbens of long-term drinking Wistar rats. Addict Biol. 2016;21:438\u201349.","journal-title":"Addict Biol"},{"key":"707_CR20","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1016\/j.euroneuro.2015.09.018","volume":"25","author":"L Khemiri","year":"2015","unstructured":"Khemiri L, Steensland P, Guterstam J, Beck O, Carlsson A, Franck J, et al. The effects of the monoamine stabilizer (-)-OSU6162 on craving in alcohol dependent individuals: A human laboratory study. Eur Neuropsychopharmacol. 2015;25:2240\u201351.","journal-title":"Eur Neuropsychopharmacol"},{"key":"707_CR21","doi-asserted-by":"crossref","unstructured":"Khemiri L, Steensland P, Guterstam J, de Manzano O, Franck J, Jayaram-Lindstrom N. Effects of the monoamine stabilizer (-)OSU6162 on cognitive function in alcohol dependence. Psychopharmacology. 2019.","DOI":"10.1007\/s00213-019-05345-6"},{"key":"707_CR22","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s00702-011-0701-y","volume":"118","author":"ES Burstein","year":"2011","unstructured":"Burstein ES, Carlsson ML, Owens M, Ma JN, Schiffer HH, Carlsson A, et al. II. In vitro evidence that (-)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors. J Neural Transm (Vienna). 2011;118:1523\u201333.","journal-title":"J Neural Transm (Vienna)"},{"key":"707_CR23","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s00702-011-0704-8","volume":"118","author":"ML Carlsson","year":"2011","unstructured":"Carlsson ML, Burstein ES, Kloberg A, Hansson S, Schedwin A, Nilsson M, et al. I. In vivo evidence for partial agonist effects of (-)-OSU6162 and (+)-OSU6162 on 5-HT2A serotonin receptors. J Neural Transm (Vienna). 2011;118:1511\u201322.","journal-title":"J Neural Transm (Vienna)"},{"key":"707_CR24","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/npp.2014.195","volume":"40","author":"N Tolboom","year":"2015","unstructured":"Tolboom N, Berendse HW, Leysen JE, Yaqub M, van Berckel BN, Schuit RC, et al. The dopamine stabilizer (-)-OSU6162 occupies a subpopulation of striatal dopamine D2\/D3 receptors: an [(11)C]raclopride PET study in healthy human subjects. Neuropsychopharmacology. 2015;40:472\u20139.","journal-title":"Neuropsychopharmacology"},{"key":"707_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejphar.2009.11.025","volume":"628","author":"T Dyhring","year":"2010","unstructured":"Dyhring T, Nielsen EO, Sonesson C, Pettersson F, Karlsson J, Svensson P, et al. The dopaminergic stabilizers Pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties. Eur J Pharmacol. 2010;628:19\u201326.","journal-title":"Eur J Pharmacol"},{"key":"707_CR26","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/(SICI)1098-2396(199804)28:4<280::AID-SYN3>3.0.CO;2-5","volume":"28","author":"J Tedroff","year":"1998","unstructured":"Tedroff J, Torstenson R, Hartvig P, Sonesson C, Waters N, Carlsson A, et al. Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements in subhuman primates: evidence for tone-dependent normalization of striatal dopaminergic activity. Synapse. 1998;28:280\u20137.","journal-title":"Synapse"},{"key":"707_CR27","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s00702-008-0038-3","volume":"115","author":"JP Rung","year":"2008","unstructured":"Rung JP, Rung E, Helgeson L, Johansson AM, Svensson K, Carlsson A, et al. Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization. J Neural Transm (Vienna). 2008;115:899\u2013908.","journal-title":"J Neural Transm (Vienna)"},{"key":"707_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4612-0357-5_3","volume-title":"Timeline Follow-Back","author":"LC Sobell","year":"1992","unstructured":"Sobell LC, Sobell MB. Timeline Follow-Back. Totowa, NJ: Humana; 1992."},{"key":"707_CR29","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0165-0327(00)00242-1","volume":"64","author":"P Svanborg","year":"2001","unstructured":"Svanborg P, Asberg M. A comparison between the Beck depression inventory (BDI) and the self-rating version of the Montgomery Asberg depression rating scale (MADRS). J Affect Disord. 2001;64:203\u201316.","journal-title":"J Affect Disord"},{"key":"707_CR30","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/j.1530-0277.1999.tb04349.x","volume":"23","author":"BA Flannery","year":"1999","unstructured":"Flannery BA, Volpicelli JR, Pettinati HM. Psychometric properties of the Penn alcohol craving scale. Alcohol Clin Exp Res. 1999;23:1289\u201395.","journal-title":"Alcohol Clin Exp Res"},{"key":"707_CR31","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00213-009-1515-6","volume":"205","author":"A Hammarberg","year":"2009","unstructured":"Hammarberg A, Jayaram-Lindstrom N, Beck O, Franck J, Reid MS. The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial. Psychopharmacology. 2009;205:53\u201362.","journal-title":"Psychopharmacology"},{"key":"707_CR32","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1046\/j.1360-0443.1998.937109113.x","volume":"93","author":"A Love","year":"1998","unstructured":"Love A, James D, Willner P. A comparison of two alcohol craving questionnaires. Addiction. 1998;93:1091\u2013102.","journal-title":"Addiction"},{"key":"707_CR33","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41467-019-09480-8","volume":"10","author":"HR Kranzler","year":"2019","unstructured":"Kranzler HR, Zhou H, Kember RL, Vickers Smith R, Justice AC, Damrauer S, et al. Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations. Nat Commun. 2019;10:1499.","journal-title":"Nat Commun"},{"key":"707_CR34","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41593-020-0643-5","volume":"23","author":"H Zhou","year":"2020","unstructured":"Zhou H, Sealock JM, Sanchez-Roige S, Clarke TK, Levey DF, Cheng Z, et al. Genome-wide meta-analysis of problematic alcohol use in 435,563 individuals yields insights into biology and relationships with other traits. Nat Neurosci. 2020;23:809\u201318.","journal-title":"Nat Neurosci"},{"key":"707_CR35","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s41586-022-05477-4","volume":"612","author":"GRB Saunders","year":"2022","unstructured":"Saunders GRB, Wang X, Chen F, Jang SK, Liu M, Wang C, et al. Genetic diversity fuels gene discovery for tobacco and alcohol use. Nature. 2022;612:720\u20134.","journal-title":"Nature"},{"key":"707_CR36","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41593-018-0326-7","volume":"22","author":"DM Howard","year":"2019","unstructured":"Howard DM, Adams MJ, Clarke TK, Hafferty JD, Gibson J, Shirali M, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat Neurosci. 2019;22:343\u201352.","journal-title":"Nat Neurosci"},{"key":"707_CR37","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/mp.2015.197","volume":"21","author":"T Otowa","year":"2016","unstructured":"Otowa T, Hek K, Lee M, Byrne EM, Mirza SS, Nivard MG, et al. Meta-analysis of genome-wide association studies of anxiety disorders. Mol Psychiatry. 2016;21:1391\u20139.","journal-title":"Mol Psychiatry"},{"key":"707_CR38","doi-asserted-by":"publisher","first-page":"giz082","DOI":"10.1093\/gigascience\/giz082","volume":"8","author":"SW Choi","year":"2019","unstructured":"Choi SW, O\u2019Reilly PF. PRSice-2: polygenic risk score software for Biobank-Scale data. GigaScience. 2019;8:giz082.","journal-title":"GigaScience"},{"key":"707_CR39","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13742-015-0047-8","volume":"4","author":"CC Chang","year":"2015","unstructured":"Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4:7.","journal-title":"Gigascience"},{"key":"707_CR40","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/ng1847","volume":"38","author":"AL Price","year":"2006","unstructured":"Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38:904\u20139.","journal-title":"Nat Genet"},{"key":"707_CR41","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/da.22771","volume":"35","author":"S Turner","year":"2018","unstructured":"Turner S, Mota N, Bolton J, Sareen J. Self-medication with alcohol or drugs for mood and anxiety disorders: A narrative review of the epidemiological literature. Depress Anxiety. 2018;35:851\u201360.","journal-title":"Depress Anxiety"},{"key":"707_CR42","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1176\/appi.ajp.2019.19030256","volume":"177","author":"DF Levey","year":"2020","unstructured":"Levey DF, Gelernter J, Polimanti R, Zhou H, Cheng Z, Aslan M, et al. Reproducible genetic risk loci for anxiety: results from approximately 200,000 participants in the million veteran program. Am J Psychiatry. 2020;177:223\u201332.","journal-title":"Am J Psychiatry"},{"key":"707_CR43","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.2217\/pgs-2020-0079","volume":"21","author":"FW Lohoff","year":"2020","unstructured":"Lohoff FW. Pharmacotherapies and personalized medicine for alcohol use disorder: a review. Pharmacogenomics. 2020;21:1117\u201338.","journal-title":"Pharmacogenomics"},{"key":"707_CR44","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1001\/archpsyc.65.2.135","volume":"65","author":"RF Anton","year":"2008","unstructured":"Anton RF, Oroszi G, O\u2019Malley S, Couper D, Swift R, Pettinati H, et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of Naltrexone response in the treatment of alcohol dependence: results from the combined pharmacotherapies and behavioral interventions for alcohol dependence (COMBINE) study. Arch Gen Psychiatry. 2008;65:135\u201344.","journal-title":"Arch Gen Psychiatry"},{"key":"707_CR45","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1530-0277.2008.00846.x","volume":"33","author":"G Oroszi","year":"2009","unstructured":"Oroszi G, Anton RF, O\u2019Malley S, Swift R, Pettinati H, Couper D, et al. OPRM1 Asn40Asp predicts response to Naltrexone treatment: a haplotype-based approach. Alcohol Clin Exp Res. 2009;33:383\u201393.","journal-title":"Alcohol Clin Exp Res"},{"key":"707_CR46","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1038\/sj.npp.1300219","volume":"28","author":"DW Oslin","year":"2003","unstructured":"Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, et al. A functional polymorphism of the mu-opioid receptor gene is associated with Naltrexone response in alcohol-dependent patients. Neuropsychopharmacology. 2003;28:1546\u201352.","journal-title":"Neuropsychopharmacology"},{"key":"707_CR47","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1001\/jamapsychiatry.2014.3053","volume":"72","author":"DW Oslin","year":"2015","unstructured":"Oslin DW, Leong SH, Lynch KG, Berrettini W, O\u2019Brien CP, Gordon AJ, et al. Naltrexone vs placebo for the treatment of alcohol dependence: A randomized clinical trial. JAMA Psychiatry. 2015;72:430\u20137.","journal-title":"JAMA Psychiatry"},{"key":"707_CR48","doi-asserted-by":"crossref","unstructured":"Logotheti M, Agioutantis P, Katsaounou P, Loutrari H. Microbiome research and Multi-Omics integration for personalized medicine in asthma. J Pers Med. 2021;11.","DOI":"10.3390\/jpm11121299"},{"key":"707_CR49","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.gim.2021.09.006","volume":"24","author":"SG Ayton","year":"2022","unstructured":"Ayton SG, Pavlicova M, Robles-Espinoza CD, Tamez Pena JG, Trevino V. Multiomics subtyping for clinically prognostic cancer subtypes and personalized therapy: A systematic review and meta-analysis. Genet Med. 2022;24:15\u201325.","journal-title":"Genet Med"},{"key":"707_CR50","doi-asserted-by":"publisher","first-page":"ofab483","DOI":"10.1093\/ofid\/ofab483","volume":"8","author":"RA Ward","year":"2021","unstructured":"Ward RA, Aghaeepour N, Bhattacharyya RP, Clish CB, Gaudilliere B, Hacohen N, et al. Harnessing the potential of multiomics studies for precision medicine in infectious disease. Open Forum Infect Dis. 2021;8:ofab483.","journal-title":"Open Forum Infect Dis"},{"key":"707_CR51","doi-asserted-by":"crossref","unstructured":"Hu C, Jia W. Multi-omics profiling: the way towards precision medicine in metabolic diseases. J Mol Cell Biol. 2021.","DOI":"10.1093\/jmcb\/mjab051"},{"key":"707_CR52","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1038\/s41598-017-02442-4","volume":"7","author":"DJ Hinton","year":"2017","unstructured":"Hinton DJ, Vazquez MS, Geske JR, Hitschfeld MJ, Ho AMC, Karpyak VM, et al. Metabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects. Sci Rep. 2017;7:2496.","journal-title":"Sci Rep"},{"key":"707_CR53","doi-asserted-by":"publisher","first-page":"e621","DOI":"10.1038\/tp.2015.120","volume":"5","author":"HW Nam","year":"2015","unstructured":"Nam HW, Karpyak VM, Hinton DJ, Geske JR, Ho AM, Prieto ML, et al. Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects. Transl Psychiatry. 2015;5:e621.","journal-title":"Transl Psychiatry"},{"key":"707_CR54","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jclinepi.2015.09.016","volume":"70","author":"JM Gaziano","year":"2016","unstructured":"Gaziano JM, Concato J, Brophy M, Fiore L, Pyarajan S, Breeling J, et al. Million veteran program: A mega-biobank to study genetic influences on health and disease. J Clin Epidemiol. 2016;70:214\u201323.","journal-title":"J Clin Epidemiol"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00707-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-025-00707-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00707-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T09:10:08Z","timestamp":1747041008000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-025-00707-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["707"],"URL":"https:\/\/doi.org\/10.1007\/s43440-025-00707-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.03.11.24304098","asserted-by":"object"}]},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}